Centessa Pharmaceuticals (NASDAQ:CNTA) is one of the best up and coming stocks to buy according to Wall Street. On January 5, Needham raised the firm’s price target on Centessa to $38 from $35 with a Buy rating on the shares. Needham suggested that Centessa’s stock momentum is poised to persist through 2026 due to the forthcoming data from the dose-escalation cohorts of the ongoing ORX-750 Phase 2a study. Consequently, the firm identified the company as one of the most compelling acquisition targets within ...

BOSTON and LONDON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced that its Board of Directors has appointed Mario Alberto Accardi PhD, President and founder of Centessa’s Orexin Program, as Chief Executive Officer (CEO) and member of the Board, effective January 1, 2026. Dr. Accardi will succeed Saurabh Saha MD PhD, who will step down from his position as CEO and a member of the Board, effective January 1, 2026. Dr. Sah ...

Centessa Pharmaceuticals (NasdaqGS:CNTA) FY Conference December 03, 2025 09:35 AM ET Company ParticipantsMario Accardi - CEOUmer Raffat - Senior Managing DirectorUmer RaffatExcited to have Centessa Management with us. I think this is a very exciting time for the company. I think you're also one of the most sought-after guys right now across buy-side as well as on the pharma side. So I'll let you kick things off, Mario.Mario AccardiThank you. Great to be here today. Thank you for the invitation. Super exciti ...

Summary of Centessa Pharmaceuticals FY Conference Call Company Overview - Centessa Pharmaceuticals is a clinical-stage biotech company focused on orexin biology and orexin agonism, particularly in the treatment of sleep disorders such as narcolepsy and idiopathic hypersomnia [2][3] Key Developments - The company recently updated its Phase 2 study results involving approximately 50-55 patients across Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), and Idiopathic Hypersomnia (IH) [2][3] - Centessa is the first company to present a robust dataset demonstrating statistically significant efficacy across all three indications [2][3] Pipeline and Future Studies - The lead asset, ORX750, is currently in Phase 2, with additional molecules ORX142 and ORX489 entering Phase 1 studies in Q1 2026 [3][4] - The company aims to expand beyond rare hypersomnias into neurodegenerative and psychiatric conditions [4] Efficacy Data - In NT1, a second dose of 1.5 mg showed a greater than 20-minute change from baseline in the Maintenance of Wakefulness Test (MWT), with half of the patients showing over 30 minutes improvement [6][7] - For NT2, a 4 mg dose resulted in a greater than 10-minute change from baseline, with the Epworth Sleepiness Scale (ESS) improving from 15-16 to 8 [7][8] - In IH, the initial 2 mg dose demonstrated clinically significant improvements in MWT and other efficacy measures [8] Safety and Tolerability - The drug has shown a favorable safety profile, with no significant adverse events reported, and only one dropout due to a pre-existing condition [31][32] Registration Program - The registration program is set to commence in Q1 2026, with flexibility to initiate across all three indications or staggered based on data from the next 50 patients [27][28] Competitive Landscape - The company believes it has a best-in-class profile based on the totality of evidence, including MWT, ESS, and tolerability metrics [34] - The orexin agonist class is viewed as having significant potential, akin to GLP-1 in the field of neurosciences [37] Intellectual Property - Centessa has developed a strong IP portfolio, with protections extending past 2040, based on unique structural biology technology [40] Conclusion - Centessa Pharmaceuticals is positioned to make significant advancements in the treatment of sleep disorders and potentially other neuropsychiatric conditions, with promising data from its lead asset and a robust pipeline [42]

Core Insights - 5AM Venture Management reduced its stake in Centessa Pharmaceuticals by 150,000 shares, now holding 680,945 shares, but the overall position value increased due to an 80% rise in stock price last quarter [2][6] - Centessa's stock price reached $29.03, reflecting a 65% increase over the past year, significantly outperforming the S&P 500's 14% gain in the same period [3][4] - The company has a market capitalization of $4.2 billion and reported a revenue of $15 million with a net loss of $242.7 million for the trailing twelve months [4] Company Overview - Centessa Pharmaceuticals is a UK-based biotechnology company focused on developing clinical-stage biopharmaceutical products for rare and serious diseases, including Lixivaptan for autosomal dominant polycystic kidney disease and SerpinPC for hemophilia [5] - The company is advancing a pipeline that targets conditions such as hemophilia, pulmonary arterial hypertension, and autoimmune diseases, serving a global patient base [5] Financial Performance - In the third quarter, Centessa reported a net loss of $54.9 million and ended the quarter with $349 million in cash and equivalents, sufficient to fund operations into mid-2027 [8] - The company announced a $250 million public offering at $21.50 per American Depositary Share (ADS) to strengthen its balance sheet [8] Market Position and Future Outlook - The decision by 5AM Venture Management to trim its position rather than exit indicates ongoing confidence in Centessa's potential, particularly in light of its promising clinical data and pipeline [6][9] - Centessa's orexin agonist platform is a key driver, with Phase 2a data showing significant improvements in wakefulness measures, and plans for a registrational program set to begin in Q1 2026 [8]

Summary of Centessa Pharmaceuticals Conference Call Company Overview - Centessa Pharmaceuticals is a clinical-stage biotech company focused on developing orexin agonists for treating excessive daytime sleepiness disorders, particularly narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH) [3][4][5] Core Insights and Arguments - **Orexin Agonists**: The company is developing a novel class of drugs targeting the orexin system, which is crucial for regulating sleep and wakefulness. The loss of orexin leads to debilitating symptoms in narcolepsy patients [3][4] - **Clinical Data**: Recent phase two study results showed significant efficacy of their lead drug, ORX750, across all three indications. The data indicated a potential best-in-class profile, particularly in NT1 and NT2 [4][6][10] - **Efficacy Metrics**: In NT1, 50% of patients achieved a mean wakefulness time (MWT) of over 30 minutes at a low dose of 1.5 mg. The Epworth Sleepiness Scale (ESS) showed a reduction of 13 points, indicating substantial improvement in patient-reported outcomes [12][13] - **Safety Profile**: The drug demonstrated a clean safety profile with no serious adverse events reported. Visual disturbances were mild and transient, not affecting the therapeutic index [20][30] - **Pharmacokinetics**: ORX750 has a flat pharmacokinetic (PK) curve, allowing for once-daily (QD) dosing, which is advantageous for patient compliance and efficacy [21][22] Market Opportunity - The combined market for NT1, NT2, and IH is estimated at $18 billion, with a prevalence of approximately 620,000 patients. There is significant unmet clinical need, as current treatments do not adequately address the symptoms for many patients [34][38] Future Plans - Centessa plans to continue its phase two studies and initiate a registration program in Q1 2026. The company has raised $270 million to support these efforts [5][33] - The company is also developing additional candidates, ORX142 and ORX489, which are expected to enter patient studies in Q1 2026 [34][37] Additional Considerations - **Dosing Flexibility**: The potential for split dosing is being evaluated to enhance symptom control for patients with varying schedules [23][24] - **Competitive Landscape**: Centessa aims to differentiate itself from competitors by focusing on the unique efficacy and tolerability of its orexin agonists [27][28] - **Long-term Vision**: The company sees orexin agonists as having broader applications beyond narcolepsy, potentially impacting various neurodegenerative disorders and cognitive functions [35] Financial Position - Centessa's balance sheet shows a proforma cash position of $620 million, providing a solid runway for ongoing and future clinical programs [39]

Core Viewpoint - Centessa Pharmaceuticals plc (NASDAQ:CNTA) has achieved a new all-time high due to a planned fundraising program that could generate up to $287.5 million in fresh funds [1][3]. Fundraising Details - Centessa plans to issue over 11.6 million new American depositary shares (ADS) at a price of $21.50 each, with each ADS representing one ordinary share [2]. - The company has granted underwriters a 30-day option to purchase an additional 1,744,186 ADS at the same price [3]. - The fundraising offer is expected to close on November 14, subject to closing conditions [3]. Financial Performance - In the third quarter, Centessa reported a widened net loss of $54.89 million, a 29% increase from $42.57 million in the same period last year [4]. - The operating loss increased by 15.9% to $53.79 million from $46.4 million year-on-year, primarily due to higher operating expenses related to research and development initiatives [4].

Summary of Centessa Pharmaceuticals FY Conference Call Company Overview - **Company**: Centessa Pharmaceuticals (NasdaqGS:CNTA) - **Event**: FY Conference on November 12, 2025 - **Presenters**: Saurabh Saha (CEO), Mario Accardi (President of the Orexin Program) Key Points Industry and Product Focus - Centessa Pharmaceuticals is not limited to narcolepsy but is exploring broader applications of its drug ORX-750, which targets orexin signaling in various neurological conditions [5][6] - The company has reported positive clinical data for ORX-750 across three indications: Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), and Idiopathic Hypersomnia (IH) [5][6] Clinical Data and Efficacy - ORX-750 has shown clinically meaningful effectiveness in NT1 and NT2, with significant changes in the Maintenance of Wakefulness Test (MWT) and Epworth Sleepiness Scale (ESS) [11][12] - In NT2, a greater than 10-point change from baseline in MWT and a drop in ESS from 16 to 8 were reported, indicating strong efficacy [11][12] - In NT1, a greater than 20-point change from baseline in MWT was observed, with half of the patients at the 1.5 mg dose showing over 30 on mean MWT [12] Drug Development Strategy - Centessa employs a real-time drug development approach, allowing for dose adjustments based on ongoing data analysis [7][8] - The company emphasizes the importance of dose-responsive data and has achieved linear exposure with dose [10] Tolerability and Safety - ORX-750 is reported to be well-tolerated, with mild adverse events (AEs) such as polyuria and insomnia, which are not dose-limiting [15][16] - The drug has shown a favorable pharmacokinetic (PK) profile, allowing for higher dose escalation without significant safety concerns [15][16] Regulatory and Market Position - Centessa plans to initiate its registration program in early 2026, with ongoing discussions with the FDA [49] - The company believes that orexin agonists will serve as monotherapy across NT1, NT2, and IH, addressing a significant unmet clinical need [43][44] Competitive Landscape - Centessa positions ORX-750 as potentially best-in-class based on its clinical data compared to competitors [11][12] - The company aims to differentiate itself by offering a drug with a robust duration of action, reducing the need for polypharmacy in patients [44][45] Future Directions - The company is exploring split dosing to provide flexibility for patients, allowing for better symptom control throughout the day [21][23] - Ongoing studies will refine the understanding of normative wakefulness thresholds and the drug's efficacy across different patient populations [27][28] Market Opportunity - The total addressable market for narcolepsy treatments is larger than current revenue figures suggest, as many patients are on generic medications that do not adequately control symptoms [48] Additional Insights - The company is focused on ensuring rigorous patient selection criteria to avoid confounding data in clinical trials [36][37] - Centessa is committed to addressing the challenges of disturbed nighttime sleep associated with narcolepsy, which is a significant concern for patients [43][44]

Group 1 - Centessa Pharmaceuticals plc has announced the pricing of an underwritten public offering of 11,627,907 American Depositary Shares (ADSs) at a price of $21.50 per ADS, with expected gross proceeds of approximately $250 million before deductions [1] - The offering is expected to close on or about November 14, 2025, subject to customary closing conditions, and includes a 30-day option for underwriters to purchase an additional 1,744,186 ADSs [1] - The ADSs are being offered under a registration statement filed with the SEC, which became effective upon filing [3] Group 2 - Jefferies, Leerink Partners, Evercore ISI, and Guggenheim Securities are acting as joint book-running managers for the offering, while Oppenheimer & Co., Truist Securities, and LifeSci Capital are co-lead managers [2] - The final prospectus supplement and accompanying prospectus related to the offering will be filed with the SEC and will be available on the SEC's website [3] Group 3 - Centessa Pharmaceuticals is a clinical-stage pharmaceutical company focused on discovering and developing transformative medicines, particularly in the area of orexin receptor 2 (OX2R) agonist program for treating excessive daytime sleepiness and other neurological disorders [5]

Core Viewpoint - Centessa Pharmaceuticals plc has initiated an underwritten public offering of American Depositary Shares (ADSs), with all shares being offered by the company, and plans to grant underwriters a 30-day option to purchase an additional 15% of the ADSs offered [1][2]. Company Overview - Centessa Pharmaceuticals is a clinical-stage pharmaceutical company focused on discovering, developing, and delivering transformative medicines for patients, particularly through its orexin receptor 2 (OX2R) agonist program aimed at treating excessive daytime sleepiness, cognitive deficits, and other neurological disorders [5]. Offering Details - The ADSs are being offered under a registration statement on Form S-3 filed with the SEC on September 11, 2024, which became effective upon filing [3]. - A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and will be accessible on the SEC's website [3]. Underwriters - Jefferies, Leerink Partners, Evercore ISI, and Guggenheim Securities are serving as joint book-running managers for the offering, while Oppenheimer & Co., Truist Securities, and LifeSci Capital are acting as co-lead managers [2]. Contact Information - For inquiries, the company has provided contact details for Kristen K. Sheppard, SVP of Investor Relations [7].